Formation Bio and Lynk Pharmaceuticals today announced Formation Bio's acquisition of worldwide rights, excluding Greater China, to LNK01006, a next generation central nervous system (CNS)–penetrant highly selective TYK2 inhibitor. The asset will be developed within Formation's newly formed subsidiary Bleecker Bio..

Formation Bio和凌科药业今天宣布，Formation Bio已获得下一代中枢神经系统（CNS）渗透性高选择性TYK2抑制剂LNK01006的全球权利（大中华区除外）。该资产将在Formation新成立的子公司Bleecker Bio内进行开发。

LNK01006 recently received IND clearance from the FDA to initiate first-in-human studies in the US. Formation Bio plans to initiate a Phase 1 study in the first half of 2026, reflecting the company's growing momentum in building a diverse portfolio of high-potential, clinical-stage assets.

LNK01006最近获得了FDA的IND批准，将在美国启动首次人体研究。Formation Bio计划在2026年上半年启动一项1期临床试验，这反映出该公司在构建多样化的高潜力临床阶段资产组合方面日益增强的动力。

LNK01006 is a next-generation, CNS-penetrant allosteric TYK2 inhibitor that combines potent, selective inhibition of TYK2-mediated cytokine signaling with a pharmacologic profile optimized for central immune modulation. Its potential best-in-class selectivity and CNS exposure are designed to regulate immune signaling within the central nervous system, potentially modulating the immune responses implicated in a range of autoimmune and inflammatory diseases.

LNK01006 是一种下一代可穿透中枢神经系统的变构 TYK2 抑制剂，它将强效、选择性抑制 TYK2 介导的细胞因子信号传导与针对中枢免疫调节优化的药理特性相结合。其潜在的同类最佳选择性和中枢神经系统暴露量旨在调控中枢神经系统内的免疫信号传导，可能调节与多种自身免疫和炎症疾病相关的免疫反应。

Its unique pharmacologic profile offers optionality to explore indications where central or compartmentalized immune pathways are believed to play a key role..

其独特的药理特性为探索中枢或局部免疫通路被认为起关键作用的适应症提供了选择性。

'This asset represents a prime example of what we call our 'Known In New' strategy of applying validated mechanisms to novel areas of high unmet need,' said David Steinberg, Chief Business Officer at Formation Bio. 'Leveraging world class human expertise, robust clinical data sets, and homegrown, state-of the-art AI tools, we've developed deeply grounded hypotheses around novel therapeutic applications of clinically derisked asset classes.'.

“该资产代表了我们所谓的‘已知新领域’战略的典型案例，即将已验证的机制应用于高度未满足需求的新领域，”Formation Bio首席商务官大卫·斯坦伯格表示。“通过利用世界级的人类专业知识、强大的临床数据集以及自主研发的最先进的AI工具，我们已经围绕临床风险降低的资产类别开发了极具深度的新治疗应用假设。”

Founded by veteran drug hunters from Johnson & Johnson, Merck, and Pfizer, Lynk Pharmaceuticals has established a broad discovery platform in immunology and inflammation. LNK01006 reflects Lynk's medicinal chemistry expertise, incorporating a highly optimized scaffold engineered for target selectivity, metabolic stability, and CNS penetration..

由来自强生、默克和辉瑞的资深药物研发专家创立，凌科药业已在免疫学和炎症领域建立了广泛的研发平台。LNK01006体现了凌科药业在药物化学方面的专业能力，融合了经过高度优化的支架结构，专为实现靶标选择性、代谢稳定性和中枢神经系统渗透而设计。

'We are excited to partner with Formation Bio to advance LNK01006 into the clinic,' said Zhao-Kui (ZK) Wan, CEO of Lynk Pharmaceuticals. 'Formation's experienced clinical development team and AI-enabled capabilities provide the ideal environment to translate this compound's scientific potential into meaningful patient impact.'.

“我们很高兴与Formation Bio合作，将LNK01006推进到临床阶段，”Lynk Pharmaceuticals首席执行官万兆奎（ZK Wan）表示，“Formation经验丰富的临床开发团队和人工智能驱动的能力为将这种化合物的科学潜力转化为对患者的有意义影响提供了理想的环境。”

Under the terms of the agreement, Lynk will receive a minority equity stake in Bleecker Bio, an upfront payment and additional development, regulatory, and commercial milestones totaling up to $605 million US dollars and tiered royalties on potential future sales. Pacific Bridge NY, a New York-based investment fund specializing in supporting companies through late preclinical and clinical development, is a minority co-investor in Bleecker Bio..

根据协议条款，Lynk将获得Bleecker Bio的少数股权、预付款以及高达6.05亿美元的开发、监管和商业里程碑付款，并在未来潜在销售额上获得分层特许权使用费。总部位于纽约的私募基金Pacific Bridge NY专注于支持公司完成晚期临床前和临床开发，是Bleecker Bio的少数共同投资者。

Formation Bio acquires and advances high-potential assets, bringing the capital, technology, and development infrastructure needed to move promising programs forward in-house. Its model combines deep therapeutic expertise, dedicated operating teams, and a proprietary AI platform that streamlines everything from asset sourcing to clinical execution – with the ultimate goal of improving development speed, efficiency, and probability of success..

Formation Bio 收购并推进高潜力资产，带来推动有前景项目所需的资本、技术和开发基础设施。其模式结合了深厚的治疗专业知识、专门的运营团队以及一个专有的人工智能平台，该平台简化了从资产寻源到临床执行的所有流程——最终目标是提高开发速度、效率和成功概率。

About Formation Bio

关于Formation Bio

Formation Bio is an AI-native pharma company differentiated by radically more efficient drug development. Formation Bio has built technology and AI platforms, processes, and capabilities to accelerate all aspects of drug development and clinical trials. Formation Bio partners, acquires, or in-licenses drugs from pharma companies and biotechs to develop programs past clinical proof of concept and beyond, leveraging their proprietary tech and AI capabilities, ultimately helping to bring new medicines to patients..

Formation Bio是一家以人工智能为核心的制药公司，其显著特点是以极高的效率进行药物开发。Formation Bio构建了技术与人工智能平台、流程和能力，以加速药物开发和临床试验的各个方面。Formation Bio通过合作、收购或许可方式从制药公司和生物技术公司引入药物，利用其专有的技术和人工智能能力，推动项目超越临床概念验证阶段及后续开发，最终助力新药惠及患者。

About Lynk Pharmaceuticals

关于凌科药业

Lynk Pharmaceuticals is a clinical stage company dedicated to discovering and developing novel medicines to treat oncology, immunology and inflammatory diseases. Lynk was founded by veteran drug hunters from Pfizer, Merck and Johnson & Johnson with collectively more than several decades of rich experiences in drug discovery.

Lynk制药是一家临床阶段的公司，致力于发现和开发治疗肿瘤学、免疫学和炎症性疾病的新药。Lynk由来自辉瑞、默克和强生的资深药物研发专家创立，他们在药物发现方面共同拥有数十年的丰富经验。

Driven by a higher purpose, Lynk aims at growing into a market leader for developing innovative therapies to address unmet medical needs..

受更高目标的驱动，Lynk 旨在成长为开发创新疗法以满足未满足医疗需求的市场领导者。

About Pacific Bridge NY

关于太平洋桥纽约

Pacific Bridge NY (PBNY) is a cross-border venture capital fund investing in emerging biotech programs with strong scientific foundations and significant global development potential. The firm partners closely with management teams, contributing to the shaping of preclinical and clinical development strategies to help accelerate advancement across key stages of growth..

太平洋桥纽约（PBNY）是一家跨境风险投资基金，专注于投资具有坚实科学基础和显著全球发展潜力的新兴生物技术项目。该机构与管理团队密切合作，参与制定临床前和临床开发策略，助力推动在成长关键阶段的快速发展。

Contact/Media:

联系/媒体：

press@formation.bio

press@formation.bio

Source: prnewswire.com

来源：prnewswire.com